SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Significant Growth in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 34,600 shares, an increase of 32.1% from the August 15th total of 26,200 shares. Based on an average trading volume of 9,400 shares, the days-to-cover ratio is presently 3.7 days. Approximately 0.5% of the shares of the stock are short sold.

Analyst Ratings Changes

Several equities analysts have issued reports on SABS shares. Oppenheimer reaffirmed an “outperform” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a report on Thursday. Brookline Capital Management assumed coverage on shares of SAB Biotherapeutics in a research note on Friday, June 7th. They issued a “buy” rating and a $8.00 price target on the stock. Chardan Capital reiterated a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.75.

SAB Biotherapeutics Stock Performance

Shares of SABS stock traded down $0.09 during trading hours on Monday, reaching $2.70. The company had a trading volume of 9,701 shares, compared to its average volume of 14,283. SAB Biotherapeutics has a 12-month low of $2.16 and a 12-month high of $10.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.24 and a quick ratio of 5.24. The stock has a fifty day moving average of $2.76 and a 200-day moving average of $3.50.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.34. The firm had revenue of $0.26 million during the quarter. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%. As a group, equities analysts forecast that SAB Biotherapeutics will post -3.59 EPS for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. RTW Investments LP purchased a new stake in SAB Biotherapeutics in the fourth quarter valued at approximately $6,310,000. BVF Inc. IL acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at $6,310,000. Commodore Capital LP purchased a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at $1,259,000. Finally, First PREMIER Bank acquired a new position in SAB Biotherapeutics during the 2nd quarter worth about $60,000. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.